Physician profile
David Cs Nickeson
NPI 1831151208
$7,151.02
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $1,459 · 2021: $1,156 · 2022: $1,190 · 2023: $1,610 · 2024: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.60 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,149.28 | 2019-2023 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $941.89 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Insmed, INC. | $805.87 | 2019-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $617.44 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $569.16 | 2019-2023 | Uptravi, Opsumit |
| Electromed, INC. | $477.90 | 2021-2023 | Smartvest |
| Sunovion Pharmaceuticals INC. | $416.16 | 2019-2021 | |
| Mylan Specialty L.P. | $356.51 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $337.03 | 2019-2024 | Dupixent |
| Harmony Biosciences LLC | $210.13 | 2020-2023 | Wakix |
| Philips North America LLC | $164.33 | 2019-2022 | |
| Pulmonx Corporation | $146.52 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Grifols USA, LLC | $134.76 | 2020-2023 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $134.56 | 2021-2023 | Acthar |
| Abbvie INC. | $118.39 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $102.26 | 2022 | |
| Shionogi INC | $87.83 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $79.71 | 2019-2023 | Xywav |
| Allergan, INC. | $73.13 | 2020 | |
| Genzyme Corporation | $56.32 | 2019-2020 | |
| Gilead Sciences, INC. | $43.73 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.77 | 2019 | |
| United Therapeutics Corporation | $32.16 | 2022-2023 | Tyvaso |
| Circassia INC. | $29.79 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nickeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.